

Applicants: Young-Choon Moon
 Application No.: 10/799,507


RECEIVED
 CENTRAL FAX CENTER

DEC 07 2006

AMENDMENTS TO THE CLAIMS

Please replace all prior versions and listings of claims with the amended claims as follows:

1. (Previously presented) A compound of formula I:



I

or a pharmaceutically acceptable salt thereof, wherein:

W is oxygen or sulfur;

ring A is a 5-6 membered aryl, heterocyclyl or heteroaryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

wherein ring A is optionally substituted with 1-4 groups independently selected from halo; aliphatic, aryl, heteroaryl or heterocyclyl, wherein said aliphatic, aryl, heteroaryl or heterocyclyl is optionally substituted with halo, $-R^2$, $-OR^2$, $-SR^2$, $-NO_2$, $-CN$, $-N(R^2)_2$, $-NR^2C(O)R^2$, $-NR^2C(O)N(R^2)_2$, $-NR^2CO_2R^2$, $-NR^2NR^2C(O)R^2$, $-NR^2NR^2C(O)N(R^2)_2$, $-NR^2NR^2CO_2R^2$, $-C(O)C(O)R^2$, $-C(O)CH_2C(O)R^2$, $-CO_2R^2$, $-C(O)R^2$, $-C(O)N(R^2)_2$, $-OC(O)N(R^2)_2$, $-S(O)_2R^2$, $-SO_2N(R^2)_2$, $-S(O)R^2$, $-NR^2SO_2R^2$, $-NR^2SO_2N(R^2)_2$, $-C(=S)N(R^2)_2$, $-C(=NH)-N(R^2)_2$, $=O$, $=S$, $=NNHR^2$, $=NN(R^2)_2$, $=NNHC(O)R^2$, $=NNHCO_2(R^2)$, $=NNHSO_2(R^2)$, or $=NR^2$, wherein two independent occurrences of R^2 , on the same substituent or different substituents, optionally taken together with the atom or atoms to which each R^2 group is bound, form a 3-8-membered cycloalkyl, heterocyclyl, aryl, or heteroaryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

$-SR^1$, $-NO_2$, $-CN$, $-N(R^1)_2$, $-NR^1C(O)R^1$, $-NR^1C(O)N(R^1)_2$, $-NR^1CO_2R^1$, $-NR^1NR^1C(O)R^1$, $-NR^1NR^1C(O)N(R^1)_2$, $-NR^1NR^1CO_2R^1$, $-C(O)C(O)R^1$, $-C(O)CH_2C(O)R^1$, $-CO_2R^1$, $-C(O)R^1$, $-C(O)N(R^1)_2$, $-OC(O)N(R^1)_2$, $-S(O)_2R^1$, $-SO_2N(R^1)_2$, $-S(O)R^1$, $-NR^1SO_2R^1$, $-NR^1SO_2N(R^1)_2$, $-C(=S)N(R^1)_2$, $-C(=NH)-N(R^1)_2$, $=O$, $=S$, $=NNHR^1$, $=NN(R^1)_2$, $=NNHC(O)R^1$, $=NNHCO_2(R^1)$, $=NNHSO_2(R^1)$, or $=NR^1$, wherein two independent occurrences of R^1 , on the

Applicants: Young-Choon Moon
 Application No.: 10/799,507

same substituent or different substituents, optionally taken together with the atom or atoms to which each R^1 group is bound, form a 3-8 membered cycloalkyl, heterocyclyl, aryl, or heteroaryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each R^1 is independently selected from hydrogen, aliphatic, aryl, heteroaryl or heterocyclyl, wherein each member of R^1 except hydrogen is optionally substituted with halo, $-R^2$, $-OR^2$, $-SR^2$, $-NO_2$, $-CN$, $-N(R^2)_2$, $-NR^2C(O)R^2$, $-NR^2C(O)N(R^2)_2$, $-NR^2CO_2R^2$, $-NR^2NR^2C(O)R^2$, $-NR^2NR^2C(O)N(R^2)_2$, $-NR^2NR^2CO_2R^2$, $-C(O)C(O)R^2$, $-C(O)CH_2C(O)R^2$, $-CO_2R^2$, $-C(O)R^2$, $-C(O)N(R^2)_2$, $-OC(O)N(R^2)_2$, $-S(O)_2R^2$, $-SO_2N(R^2)_2$, $-S(O)R^2$, $-NR^2SO_2R^2$, $-NR^2SO_2N(R^2)_2$, $-C(=S)N(R^2)_2$, $-C(=NH)-N(R^2)_2$, $=O$, $=S$, $=NNHR^2$, $=NN(R^2)_2$, $=NNHC(O)R^2$, $=NNHCO_2(R^2)$, $=NNHSO_2(R^2)$, or $=NR^2$, wherein two independent occurrences of R^2 , on the same substituent or different substituents, optionally taken together with the atom or atoms to which each R^2 group is bound, form a 3-8-membered cycloalkyl, heterocyclyl, aryl, or heteroaryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each R^2 is independently selected from hydrogen, aliphatic, aryl, heteroaryl or heterocyclyl, wherein each member of R^2 except hydrogen is optionally substituted with halo, $-R^3$, $-OR^3$, $-SR^3$, $-NO_2$, $-CN$, $-N(R^3)_2$, $-NR^3C(O)R^3$, $-NR^3C(O)N(R^3)_2$, $-NR^3CO_2R^3$, $-NR^3NR^3C(O)R^3$, $-NR^3NR^3C(O)N(R^3)_2$, $-NR^3NR^3CO_2R^3$, $-C(O)C(O)R^3$, $-C(O)CH_2C(O)R^3$, $-CO_2R^3$, $-C(O)R^3$, $-C(O)N(R^3)_2$, $-OC(O)N(R^3)_2$, $-S(O)_2R^3$, $-SO_2N(R^3)_2$, $-S(O)R^3$, $-NR^3SO_2R^3$, $-NR^3SO_2N(R^3)_2$, $-C(=S)N(R^3)_2$, $-C(=NH)-N(R^3)_2$, $=O$, $=S$, $=NNHR^3$, $=NN(R^3)_2$, $=NNHC(O)R^3$, $=NNHCO_2(R^3)$, $=NNHSO_2(R^3)$, or $=NR^3$; and

each R^3 is independently hydrogen or unsubstituted aliphatic;
 provided that when ring A is phenyl, it must be substituted.

2. (Original) The compound of claim 1, wherein W is oxygen.
3. (Original) The compound of claim 1, wherein W is sulfur.
4. (Previously presented) The compound of claim 2 or 3, wherein ring A is phenyl substituted with 1-4 groups independently selected from halo; aliphatic, aryl, heteroaryl or heterocyclyl, wherein said aliphatic, aryl, heteroaryl or heterocyclyl is

Applicants: Young-Choon Moon
 Application No.: 10/799,507

optionally substituted with halo, $-R^2$, $-OR^2$, $-SR^2$, $-NO_2$, $-CN$, $-N(R^2)_2$, $-NR^2C(O)R^2$, $-NR^2C(O)N(R^2)_2$, $-NR^2CO_2R^2$, $-NR^2NR^2C(O)R^2$, $-NR^2NR^2C(O)N(R^2)_2$, $-NR^2NR^2CO_2R^2$, $-C(O)C(O)R^2$, $-C(O)CH_2C(O)R^2$, $-CO_2R^2$, $-C(O)R^2$, $-C(O)N(R^2)_2$, $-OC(O)N(R^2)_2$, $-S(O)_2R^2$, $-SO_2N(R^2)_2$, $-S(O)R^2$, $-NR^2SO_2R^2$, $-NR^2SO_2N(R^2)_2$, $-C(=S)N(R^2)_2$, $-C(=NH)-N(R^2)_2$, $=O$, $=S$, $=NNHR^2$, $=NN(R^2)_2$, $=NNHC(O)R^2$, $=NNHCO_2(R^2)$, $=NNHSO_2(R^2)$, or $=NR^2$, wherein two independent occurrences of R^2 , on the same substituent or different substituents, optionally taken together with the atom or atoms to which each R^2 group is bound, form a 3-8-membered cycloalkyl, heterocyclyl, aryl, or heteroaryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; $-SR^1$, $-NO_2$, $-CN$, $-N(R^1)_2$, $-NR^1C(O)R^1$, $-NR^1C(O)N(R^1)_2$, $-NR^1CO_2R^1$, $-NR^1NR^1C(O)R^1$, $-NR^1NR^1C(O)N(R^1)_2$, $-NR^1NR^1CO_2R^1$, $-C(O)C(O)R^1$, $-C(O)CH_2C(O)R^1$, $-CO_2R^1$, $-C(O)R^1$, $-C(O)N(R^1)_2$, $-OC(O)N(R^1)_2$, $-S(O)_2R^1$, $-SO_2N(R^1)_2$, $-S(O)R^1$, $-NR^1SO_2R^1$, $-NR^1SO_2N(R^1)_2$, $-C(=S)N(R^1)_2$, or $-C(=NH)-N(R^1)_2$, wherein two independent occurrences of R^1 , on the same substituent or different substituents, optionally taken together with the atom or atoms to which each R^1 group is bound, form a 5-7-membered cycloalkyl, heterocyclyl, aryl, or heteroaryl ring having 0-2 heteroatoms independently selected from N, O or S.


5. (Previously presented) The compound of claim 4, wherein ring A is phenyl substituted with 1-4 groups independently selected from halo; aliphatic, aryl, heteroaryl or heterocyclyl, wherein said aliphatic, aryl, heteroaryl or heterocyclyl is optionally substituted with halo, $-R^2$, $-OR^2$, $-SR^2$, $-NO_2$, $-CN$, $-N(R^2)_2$, $-NR^2C(O)R^2$, $-NR^2C(O)N(R^2)_2$, $-NR^2CO_2R^2$, $-NR^2NR^2C(O)R^2$, $-NR^2NR^2C(O)N(R^2)_2$, $-NR^2NR^2CO_2R^2$, $-C(O)C(O)R^2$, $-C(O)CH_2C(O)R^2$, $-CO_2R^2$, $-C(O)R^2$, $-C(O)N(R^2)_2$, $-OC(O)N(R^2)_2$, $-S(O)_2R^2$, $-SO_2N(R^2)_2$, $-S(O)R^2$, $-NR^2SO_2R^2$, $-NR^2SO_2N(R^2)_2$, $-C(=S)N(R^2)_2$, $-C(=NH)-N(R^2)_2$, $=O$, $=S$, $=NNHR^2$, $=NN(R^2)_2$, $=NNHC(O)R^2$, $=NNHCO_2(R^2)$, $=NNHSO_2(R^2)$, or $=NR^2$, wherein two independent occurrences of R^2 , on the same substituent or different substituents, optionally taken together with the atom or atoms to which each R^2 group is bound, form a 3-8-membered cycloalkyl, heterocyclyl, aryl, or heteroaryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; $-SR^1$, $-NO_2$, $-CN$, $-N(R^1)_2$, $-NR^1C(O)R^1$, $-CO_2R^1$, $-C(O)R^1$, $-C(O)N(R^1)_2$, $-S(O)_2R^1$, $-SO_2N(R^1)_2$, $-NR^1SO_2R^1$, or $-C(=S)N(R^1)_2$, wherein two independent occurrences of R^1 , on the same substituent or different substituents, optionally taken together

Applicants: Young-Choon Moon
 Application No.: 10/799,507

with the atom or atoms to which each R^1 group is bound, form a 5-7-membered heterocyclyl, aryl, or heteroaryl ring having 0-2 heteroatoms independently selected from N, O or S.

6. (Previously presented) The compound of claim 21, wherein ring A is a 5-6 membered heterocyclyl or heteroaryl ring having 1-2 heteroatoms independently selected from N, O or S, wherein ring A is optionally substituted with 1-4 groups independently selected from halo, $-R^1$, $-OR^1$, $-SR^1$, $-NO_2$, $-CN$, $-N(R^1)_2$, $-NR^1C(O)R^1$, $-CO_2R^1$, $-C(O)R^1$, $-C(O)N(R^1)_2$, $-S(O)_2R^1$, $-SO_2N(R^1)_2$, $-NR^1SO_2R^1$, or $-C(=S)N(R^1)_2$, wherein two independent occurrences of R^1 , on the same substituent or different substituents, optionally taken together with the atom or atoms to which each R^1 group is bound, form a 5-7-membered cycloalkyl, heterocyclyl, aryl, or heteroaryl ring having 0-2 heteroatoms independently selected from N, O or S.

7. (Previously presented) A compound of formula I:



I

or a pharmaceutically acceptable salt thereof, wherein:

W is oxygen or sulfur;

ring A is naphthyl, benzodioxolyl, dihydrobenzodioxinyl, benzothiazolyl, benzoimidazolyl, or dihydrobenzo[b][1,4]dioxepinyl, wherein each member of ring A is optionally substituted with halo, $-R^2$, $-OR^2$, $-SR^2$, $-NO_2$, $-CN$, $-N(R^2)_2$, $-NR^2C(O)R^2$, $-CO_2R^2$, $-C(O)R^2$, $-C(O)N(R^2)_2$, $-S(O)_2R^2$, $-SO_2N(R^2)_2$, $-NR^2SO_2R^2$, or $-C(=S)N(R^2)_2$;

each R^2 is independently selected from hydrogen, aliphatic, aryl, heteroaryl or heterocyclyl, wherein each member of R^2 except hydrogen is optionally substituted with halo, $-R^3$, $-OR^3$, $-SR^3$, $-NO_2$, $-CN$, $-N(R^3)_2$, $-NR^3C(O)R^3$, $-NR^3C(O)N(R^3)_2$, $-NR^3CO_2R^3$, $-NR^3NR^3C(O)R^3$, $-NR^3NR^3C(O)N(R^3)_2$, $-NR^3NR^3CO_2R^3$, $-C(O)C(O)R^3$, $-C(O)CH_2C(O)R^3$, $-CO_2R^3$, $-C(O)R^3$, $-C(O)N(R^3)_2$, $-OC(O)N(R^3)_2$, $-S(O)_2R^3$, $-SO_2N(R^3)_2$, $-S(O)R^3$, $-NR^3SO_2R^3$,


Applicants: Young-Choon Moon
 Application No.: 10/799,507

$-\text{NR}^3\text{SO}_2\text{N}(\text{R}^3)_2$, $-\text{C}(=\text{S})\text{N}(\text{R}^3)_2$, $-\text{C}(=\text{NH})-\text{N}(\text{R}^3)_2$, $=\text{O}$, $=\text{S}$, $=\text{NNHR}^3$, $=\text{NN}(\text{R}^3)_2$,
 $=\text{NNHC}(\text{O})\text{R}^3$, $=\text{NNHCO}_2(\text{R}^3)$, $=\text{NNHSO}_2(\text{R}^3)$, or $=\text{NR}^3$; and


each R^3 is independently hydrogen or unsubstituted aliphatic.

8. (Previously presented) The compound of claim 21, wherein ring A is pyridinonyl, tetrahydro-quinolinyl, pyridyl, or thiazolyl, wherein each member of ring A is optionally substituted with halo, $-\text{R}^2$, $-\text{OR}^2$, $-\text{SF}_2$, $-\text{NO}_2$, $-\text{CN}$, $-\text{N}(\text{R}^2)_2$, $-\text{NR}^2\text{C}(\text{O})\text{R}^2$, $-\text{CO}_2\text{R}^2$, $-\text{C}(\text{O})\text{R}^2$, $-\text{C}(\text{O})\text{N}(\text{R}^2)_2$, $-\text{S}(\text{O})_2\text{R}^2$, $-\text{SO}_2\text{N}(\text{R}^2)_2$, $-\text{NR}^2\text{SO}_2\text{R}^2$, or $-\text{C}(=\text{S})\text{N}(\text{R}^2)_2$.


9. (Previously presented) A compound selected from:




I-3




I-4




I-5




I-6



I-7




I-8




I-10


Applicants: Young-Choon Moon
Application No.: 10/799,507




I-11




I-12




I-13




I-14




I-15




I-16




I-17



I-18




I-19




I-20


Applicants: Young-Choon Moon
Application No.: 10/799,507




I-21




I-22




I-23




I-24




I-25




I-26




I-27



I-28




I-29




I-30


Applicants: Young-Choon Moon
Application No.: 10/799,507




I-31




I-32




I-33




I-34




I-35




I-36




I-37



I-38













I-39













I-40


Applicants: Young-Choon Moon
Application No.: 10/799,507




Applicants: Young-Choon Moon
Application No.: 10/799,507




Applicants: Young-Choon Moon
Application No.: 10/799,507




I-61




I-62




I-63




I-64




I-65




I-66



I-67



I-68



I-69.


Applicants: Young-Choon Moon
 Application No.: 10/799,507

10. (Previously presented) A composition comprising a compound of claim 1, 7, 9, 21 or 22, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

11. (Previously presented) The composition of claim 10, additionally comprising an agent for treating diabetes.

12 to 16. (Canceled).

17. (Previously presented) A method of treating or lessening the severity of diabetes in a patient, comprising administering to said patient a compound of formula I:



I

or a pharmaceutically acceptable salt thereof, wherein:

W is oxygen or sulfur;

ring A is a 5-6 membered aryl, heterocyclcyl or heteroaryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

wherein ring A is optionally substituted with 1-4 groups independently selected from halo, $-R^1$, $-OR^1$, $-SR^1$, $-NO_2$, $-CN$, $-N(R^1)_2$, $-NR^1C(O)R^1$, $-NR^1C(O)N(R^1)_2$, $-NR^1CO_2R^1$, $-NR^1NR^1C(O)R^1$, $-NR^1NR^1C(O)N(R^1)_2$, $-NR^1NR^1CO_2R^1$, $-C(O)C(O)R^1$, $-C(O)CH_2C(O)R^1$, $-CO_2R^1$, $-C(O)R^1$, $-C(O)N(R^1)_2$, $-OC(O)N(R^1)_2$, $-S(O)_2R^1$, $-SO_2N(R^1)_2$, $-S(O)R^1$, $-NR^1SO_2R^1$, $-NR^1SO_2N(R^1)_2$, $-C(=S)N(R^1)_2$, $-C(=NH)N(R^1)_2$, $=O$, $=S$, $=NNHR^1$, $=NN(R^1)_2$, $=NNHC(O)R^1$, $=NNHCO_2(R^1)$, $=NNHSO_2(R^1)$, or $=NR^1$, wherein two independent occurrences of R^1 , on the same substituent or different substituents, optionally taken together with the atom or atoms to which each R^1 group is bound, form a 3-8-membered cycloalkyl, heterocyclcyl, aryl, or heteroaryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each R^1 is independently selected from hydrogen, aliphatic, aryl, heteroaryl or heterocyclcyl, wherein each member of R^1 except hydrogen is optionally substituted with halo,

Applicants: Young-Choon Moon
 Application No.: 10/799,507

$-R^2$, $-OR^2$, $-SR^2$, $-NO_2$, $-CN$, $-N(R^2)_2$, $-NR^2C(O)R^2$, $-NR^2C(O)N(R^2)_2$, $-NR^2CO_2R^2$, $-NR^2NR^2C(O)R^2$, $-NR^2NR^2C(O)N(R^2)_2$, $-NR^2NR^2CO_2R^2$, $-C(O)C(O)R^2$, $-C(O)CH_2C(O)R^2$, $-CO_2R^2$, $-C(O)R^2$, $-C(O)N(R^2)_2$, $-OC(O)N(R^2)_2$, $-S(O)_2R^2$, $-SO_2N(R^2)_2$, $-S(O)R^2$, $-NR^2SO_2R^2$, $-NR^2SO_2N(R^2)_2$, $-C(=S)N(R^2)_2$, $-C(=NH)-N(R^2)_2$, $=O$, $=S$, $=NNHR^2$, $=NN(R^2)_2$, $=NNHC(O)R^2$, $=NNHCO_2(R^2)$, $=NNHSO_2(R^2)$, or $=NR^2$, wherein two independent occurrences of R^2 , on the same substituent or different substituents, optionally taken together with the atom or atoms to which each R^2 group is bound, form a 3-8-membered cycloalkyl, heterocyclyl, aryl, or heteroaryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;


each R^2 is independently selected from hydrogen, aliphatic, aryl, heteroaryl or heterocyclyl, wherein each member of R^2 except hydrogen is optionally substituted with halo, $-R^3$, $-OR^3$, $-SR^3$, $-NO_2$, $-CN$, $-N(R^3)_2$, $-NR^3C(O)R^3$, $-NR^3C(O)N(R^3)_2$, $-NR^3CO_2R^3$, $-NR^3NR^3C(O)R^3$, $-NR^3NR^3C(O)N(R^3)_2$, $-NR^3NR^3CO_2R^3$, $-C(O)C(O)R^3$, $-C(O)CH_2C(O)R^3$, $-CO_2R^3$, $-C(O)R^3$, $-C(O)N(R^3)_2$, $-OC(O)N(R^3)_2$, $-S(O)_2R^3$, $-SO_2N(R^3)_2$, $-S(O)R^3$, $-NR^3SO_2R^3$, $-NR^3SO_2N(R^3)_2$, $-C(=S)N(R^3)_2$, $-C(=NH)-N(R^3)_2$, $=O$, $=S$, $=NNHR^3$, $=NN(R^3)_2$, $=NNHC(O)R^3$, $=NNHCO_2(R^3)$, $=NNHSO_2(R^3)$, or $=NR^3$; and

each R^3 is independently hydrogen or unsubstituted aliphatic; or

a pharmaceutical composition comprising said compound and a pharmaceutically acceptable carrier, adjuvant, or vehicle;

in an amount effective to treat or lessen the severity of diabetes in said patient.

18. (Previously presented) A method of treating or lessening the severity of stroke in a patient, comprising administering to said patient a compound of formula I:



I

or a pharmaceutically acceptable salt thereof, wherein:

W is oxygen or sulfur;

Applicants: Young-Choon Moon
 Application No.: 10/799,507

ring A is a 5-6 membered aryl, heterocyclyl or heteroaryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

wherein ring A is optionally substituted with 1-4 groups independently selected from halo, $-R^1$, $-OR^1$, $-SR^1$, $-NO_2$, $-CN$, $-N(R^1)_2$, $-NR^1C(O)R^1$, $-NR^1C(O)N(R^1)_2$, $-NR^1CO_2R^1$, $-NR^1NR^1C(O)R^1$, $-NR^1NR^1C(O)N(R^1)_2$, $-NR^1NR^1CO_2R^1$, $-C(O)C(O)R^1$, $-C(O)CH_2C(O)R^1$, $-CO_2R^1$, $-C(O)R^1$, $-C(O)N(R^1)_2$, $-OC(O)N(R^1)_2$, $-S(O)_2R^1$, $-SO_2N(R^1)_2$, $-S(O)R^1$, $-NR^1SO_2R^1$, $-NR^1SO_2N(R^1)_2$, $-C(=S)N(R^1)_2$, $-C(=NH)-N(R^1)_2$, $=O$, $=S$, $=NNHR^1$, $=NN(R^1)_2$, $=NNHC(O)R^1$, $=NNHCO_2(R^1)$, $=NNHSO_2(R^1)$, or $=NR^1$, wherein two independent occurrences of R^1 , on the same substituent or different substituents, optionally taken together with the atom or atoms to which each R^1 group is bound, form a 3-8-membered cycloalkyl, heterocyclyl, aryl, or heteroaryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each R^1 is independently selected from hydrogen, aliphatic, aryl, heteroaryl or heterocyclyl, wherein each member of R^1 except hydrogen is optionally substituted with halo, $-R^2$, $-OR^2$, $-SR^2$, $-NO_2$, $-CN$, $-N(R^2)_2$, $-NR^2C(O)R^2$, $-NR^2C(O)N(R^2)_2$, $-NR^2CO_2R^2$, $-NR^2NR^2C(O)R^2$, $-NR^2NR^2C(O)N(R^2)_2$, $-NR^2NR^2CO_2R^2$, $-C(O)C(O)R^2$, $-C(O)CH_2C(O)R^2$, $-CO_2R^2$, $-C(O)R^2$, $-C(O)N(R^2)_2$, $-OC(O)N(R^2)_2$, $-S(O)_2R^2$, $-SO_2N(R^2)_2$, $-S(O)R^2$, $-NR^2SO_2R^2$, $-NR^2SO_2N(R^2)_2$, $-C(=S)N(R^2)_2$, $-C(=NH)-N(R^2)_2$, $=O$, $=S$, $=NNHR^2$, $=NN(R^2)_2$, $=NNHC(O)R^2$, $=NNHCO_2(R^2)$, $=NNHSO_2(R^2)$, or $=NR^2$, wherein two independent occurrences of R^2 , on the same substituent or different substituents, optionally taken together with the atom or atoms to which each R^2 group is bound, form a 3-8-membered cycloalkyl, heterocyclyl, aryl, or heteroaryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each R^2 is independently selected from hydrogen, aliphatic, aryl, heteroaryl or heterocyclyl, wherein each member of R^2 except hydrogen is optionally substituted with halo, $-R^3$, $-OR^3$, $-SR^3$, $-NO_2$, $-CN$, $-N(R^3)_2$, $-NR^3C(O)R^3$, $-NR^3C(O)N(R^3)_2$, $-NR^3CO_2R^3$, $-NR^3NR^3C(O)R^3$, $-NR^3NR^3C(O)N(R^3)_2$, $-NR^3NR^3CO_2R^3$, $-C(O)C(O)R^3$, $-C(O)CH_2C(O)R^3$, $-CO_2R^3$, $-C(O)R^3$, $-C(O)N(R^3)_2$, $-OC(O)N(R^3)_2$, $-S(O)_2R^3$, $-SO_2N(R^3)_2$, $-S(O)R^3$, $-NR^3SO_2R^3$, $-NR^3SO_2N(R^3)_2$, $-C(=S)N(R^3)_2$, $-C(=NH)-N(R^3)_2$, $=O$, $=S$, $=NNHR^3$, $=NN(R^3)_2$, $=NNHC(O)R^3$, $=NNHCO_2(R^3)$, $=NNHSO_2(R^3)$, or $=NR^3$; and


each R^3 is independently hydrogen or unsubstituted aliphatic; or

Applicants: Young-Choon Moon
Application No.: 10/799,507

a pharmaceutical composition comprising said compound and a pharmaceutically acceptable carrier, adjuvant, or vehicle;


in an amount effective to treat or lessen the severity of stroke in said patient.

19. (Previously presented) The method according to claim 18, wherein said method comprises administering to said patient: compound I-1:




I-1


or a compound selected from:




I-2




I-3




I-4



I-5




I-6




I-7


Applicants: Young-Choon Moon
Application No.: 10/799,507




I-8




I-10




I-11



I-12




I-13




I-14




I-15



I-16




I-17




I-18


Applicants: Young-Choon Moon
Application No.: 10/799,507




I-19




I-20




I-21




I-22




I-23




I-24




I-25



I-26




I-27




I-28


Applicants: Young-Choon Moon
Application No.: 10/799,507




I-29




I-30




I-31




I-32




I-33




I-34




I-35



I-36




I-37




I-38


Applicants: Young-Choon Moon
Application No.: 10/799,507




I-39




I-40




I-41




I-42




I-43




I-44




I-45



I-46




I-47




I-48


Applicants: Young-Choon Moon
Application No.: 10/799,507




I-49




I-50




I-51




I-52




I-53




I-54




I-55



I-56




I-57




I-58


Applicants: Young-Choon Moon
Application No.: 10/799,507




I-59




I-60




I-61




I-62




I-63




I-64




I-65



I-66




I-67



I-68

Applicants: Young-Choon Moon
 Application No.: 10/799,507



or


I-69, or

a pharmaceutical composition comprising said compound and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

20. (Previously presented) The method according to claim 18, comprising the additional step of administering to said patient an additional therapeutic agent for treating stroke, wherein:

said additional therapeutic agent is administered together with said composition as a single dosage form or separately from said composition as part of a multiple dosage form.

21. (Previously presented) A compound of formula I:



I.

or a pharmaceutically acceptable salt thereof, wherein:

W is oxygen or sulfur;

ring A is a 5-6 membered heterocyclyl or heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

wherein ring A is optionally substituted with 1-4 groups independently selected from halo, $-R^1$, $-OR^1$, $-SR^1$, $-NO_2$, $-CN$, $-N(R^1)_2$, $-NR^1C(O)R^1$, $-NR^1C(O)N(R^1)_2$, $-NR^1CO_2R^1$, $-NR^1NR^1C(O)R^1$, $-NR^1NR^1C(O)N(R^1)_2$, $-NR^1NR^1CO_2R^1$, $-C(O)C(O)R^1$, $-C(O)CH_2C(O)R^1$, $-CO_2R^1$, $-C(O)R^1$, $-C(O)N(R^1)_2$, $-OC(O)N(R^1)_2$, $-S(O)_2R^1$, $-SO_2N(R^1)_2$, $-S(O)R^1$, $-NR^1SO_2R^1$, $-NR^1SO_2N(R^1)_2$, $-C(=S)N(R^1)_2$, $-C(=NH)-N(R^1)_2$, $=O$, $=S$, $=NNHR^1$, $=NN(R^1)_2$,

Applicants: Young-Choon Moon

Application No.: 10/799,507


$=\text{NNHC}(\text{O})\text{R}^1$, $=\text{NNHCO}_2(\text{R}^1)$, $=\text{NNHSO}_2(\text{R}^1)$, or $=\text{NR}^1$, wherein two independent occurrences of R^1 , on the same substituent or different substituents, optionally taken together with the atom or atoms to which each R^1 group is bound, form a 3-8 membered cycloalkyl, heterocyclyl, aryl, or heteroaryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each R^1 is independently selected from hydrogen, aliphatic, aryl, heteroaryl or heterocyclyl, wherein each member of R^1 except hydrogen is optionally substituted with halo, $-\text{R}^2$, $-\text{OR}^2$, $-\text{SR}^2$, $-\text{NO}_2$, $-\text{CN}$, $-\text{N}(\text{R}^2)_2$, $-\text{NR}^2\text{C}(\text{O})\text{R}^2$, $-\text{NR}^2\text{C}(\text{O})\text{N}(\text{R}^2)_2$, $-\text{NR}^2\text{CO}_2\text{R}^2$, $-\text{NR}^2\text{NR}^2\text{C}(\text{O})\text{R}^2$, $-\text{NR}^2\text{NR}^2\text{C}(\text{O})\text{N}(\text{R}^2)_2$, $-\text{NR}^2\text{NR}^2\text{CO}_2\text{R}^2$, $-\text{C}(\text{O})\text{C}(\text{O})\text{R}^2$, $-\text{C}(\text{O})\text{CH}_2\text{C}(\text{O})\text{R}^2$, $-\text{CO}_2\text{R}^2$, $-\text{C}(\text{O})\text{R}^2$, $-\text{C}(\text{O})\text{N}(\text{R}^2)_2$, $-\text{OC}(\text{O})\text{N}(\text{R}^2)_2$, $-\text{S}(\text{O})_2\text{R}^2$, $-\text{SO}_2\text{N}(\text{R}^2)_2$, $-\text{S}(\text{O})\text{R}^2$, $-\text{NR}^2\text{SO}_2\text{R}^2$, $-\text{NR}^2\text{SO}_2\text{N}(\text{R}^2)_2$, $-\text{C}(=\text{S})\text{N}(\text{R}^2)_2$, $-\text{C}(=\text{NH})\text{N}(\text{R}^2)_2$, $=\text{O}$, $=\text{S}$, $=\text{NNHR}^2$, $=\text{NN}(\text{R}^2)_2$, $=\text{NNHC}(\text{O})\text{R}^2$, $=\text{NNHCO}_2(\text{R}^2)$, $=\text{NNHSO}_2(\text{R}^2)$, or $=\text{NR}^2$, wherein two independent occurrences of R^2 , on the same substituent or different substituents, optionally taken together with the atom or atoms to which each R^2 group is bound, form a 3-8-membered cycloalkyl, heterocyclyl, aryl, or heteroaryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each R^2 is independently selected from hydrogen, aliphatic, aryl, heteroaryl or heterocyclyl, wherein each member of R^2 except hydrogen is optionally substituted with halo, $-\text{R}^3$, $-\text{OR}^3$, $-\text{SR}^3$, $-\text{NO}_2$, $-\text{CN}$, $-\text{N}(\text{R}^3)_2$, $-\text{NR}^3\text{C}(\text{O})\text{R}^3$, $-\text{NR}^3\text{C}(\text{O})\text{N}(\text{R}^3)_2$, $-\text{NR}^3\text{CO}_2\text{R}^3$, $-\text{NR}^3\text{NR}^3\text{C}(\text{O})\text{R}^3$, $-\text{NR}^3\text{NR}^3\text{C}(\text{O})\text{N}(\text{R}^3)_2$, $-\text{NR}^3\text{NR}^3\text{CO}_2\text{R}^3$, $-\text{C}(\text{O})\text{C}(\text{O})\text{R}^3$, $-\text{C}(\text{O})\text{CH}_2\text{C}(\text{O})\text{R}^3$, $-\text{CO}_2\text{R}^3$, $-\text{C}(\text{O})\text{R}^3$, $-\text{C}(\text{O})\text{N}(\text{R}^3)_2$, $-\text{OC}(\text{O})\text{N}(\text{R}^3)_2$, $-\text{S}(\text{O})_2\text{R}^3$, $-\text{SO}_2\text{N}(\text{R}^3)_2$, $-\text{S}(\text{O})\text{R}^3$, $-\text{NR}^3\text{SO}_2\text{R}^3$, $-\text{NR}^3\text{SO}_2\text{N}(\text{R}^3)_2$, $-\text{C}(=\text{S})\text{N}(\text{R}^3)_2$, $-\text{C}(=\text{NH})\text{N}(\text{R}^3)_2$, $=\text{O}$, $=\text{S}$, $=\text{NNHR}^3$, $=\text{NN}(\text{R}^3)_2$, $=\text{NNHC}(\text{O})\text{R}^3$, $=\text{NNHCO}_2(\text{R}^3)$, $=\text{NNHSO}_2(\text{R}^3)$, or $=\text{NR}^3$; and

each R^3 is independently hydrogen or unsubstituted aliphatic.

22. (Previously presented) A compound of formula I:




Applicants: Young-Choon Moon
Application No.: 10/799,507

II


or a pharmaceutically acceptable salt thereof, wherein:

W is oxygen or sulfur; and


ring A is selected from:




Applicants: Young-Choon Moon
Application No.: 10/799,507



Applicants: Young-Choon Moon
 Application No.: 10/799,507




23. (Previously presented) The method according to claim 17, wherein said method comprises administering to said patient compound **I-1**:




I-1

or a compound selected from:


Applicants: Young-Choon Moon
Application No.: 10/799,507




I-2




I-3




I-4




I-5




I-6




I-7




I-8



I-10




I-11




I-12


Applicants: Young-Choon Moon
Application No.: 10/799,507




I-13




I-14




I-15




I-16




I-17




I-18




I-19



I-20




I-21




I-22


Applicants: Young-Choon Moon
Application No.: 10/799,507




I-23




I-24




I-25




I-26




I-27




I-28




I-29



I-30













I-31




I-32


Applicants: Young-Choon Moon
Application No.: 10/799,507




Applicants: Young-Choon Moon
Application No.: 10/799,507




I-43




I-44




I-45




I-46




I-47




I-48




I-49



I-50




I-51




I-52


Applicants: Young-Choon Moon
Application No.: 10/799,507




I-53




I-54




I-55




I-56




I-57




I-58




I-59



I-60




I-61




I-62


Applicants: Young-Choon Moon
 Application No.: 10/799,507




I-63




I-64




I-65




I-66



I-67



I-68



or

I-69, or

a pharmaceutical composition comprising said compound and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

24. (Previously presented) The method according to claim 23, comprising the additional step of administering to said patient an additional therapeutic agent for treating diabetes, wherein:

said additional therapeutic agent is administered together with said composition as a single dosage form or separately from said composition as part of a multiple dosage form.

Applicants: Young-Choon Moon
Application No.: 10/799,507

25. (Previously presented) The method according to claim 17, comprising the additional step of administering to said patient an additional therapeutic agent for treating diabetes, wherein:

said additional therapeutic agent is administered together with said composition as a single dosage form or separately from said composition as part of a multiple dosage form.

26. (Previously presented) The method according to claim 19, comprising the additional step of administering to said patient an additional therapeutic agent for treating stroke, wherein:

said additional therapeutic agent is administered together with said composition as a single dosage form or separately from said composition as part of a multiple dosage form.